113 related articles for article (PubMed ID: 38108195)
1. Correction to Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
Clin Pharmacol Ther; 2024 Feb; 115(2):372. PubMed ID: 38108195
[No Abstract] [Full Text] [Related]
2. Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
Rodrigues AD; Wood LS; Vourvahis M; Rowland A
Clin Pharmacol Ther; 2022 Feb; 111(2):425-434. PubMed ID: 34623637
[TBL] [Abstract][Full Text] [Related]
3. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Kharasch ED; Russell M; Mautz D; Thummel KE; Kunze KL; Bowdle A; Cox K
Anesthesiology; 1997 Jul; 87(1):36-50. PubMed ID: 9232132
[TBL] [Abstract][Full Text] [Related]
4. Regulation of human pregnane X receptor and its target gene cytochrome P450 3A by praeruptorin A isolated from the herbal medicine Peucedanum praeruptorum.
Huang L; Bi HC; Li YH; Zhang JQ; Kuang SY; Zhang L; Wang YT; Huang M
Planta Med; 2013 Nov; 79(16):1509-15. PubMed ID: 24037590
[TBL] [Abstract][Full Text] [Related]
5. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes.
Patten CJ; Smith TJ; Friesen MJ; Tynes RE; Yang CS; Murphy SE
Carcinogenesis; 1997 Aug; 18(8):1623-30. PubMed ID: 9276639
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.
Lin HL; Zhang H; Medower C; Hollenberg PF; Johnson WW
Drug Metab Dispos; 2011 Feb; 39(2):345-50. PubMed ID: 21068193
[TBL] [Abstract][Full Text] [Related]
7. A Promising Approach to Treat Psoriasis: Inhibiting Cytochrome P450 3A4 Metabolism to Enhance Desoximetasone Therapy.
Guo JW; Cheng YP; Lim CJ; Liu CY; Jee SH
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631230
[TBL] [Abstract][Full Text] [Related]
8. Correction to Exploring the Use of Serum-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Hepatic Cytochromes P450 and Organic Anion Transporting Polypeptides.
Clin Pharmacol Ther; 2024 Feb; 115(2):371. PubMed ID: 38111152
[No Abstract] [Full Text] [Related]
9. [Electroanalytical and electrocatalytical characteristics of cytochrome P450 3A4 using electrodes modified with nanocomposite carbon nanomaterials].
Kuzikov AV; Bulko TV; Koroleva PI; Masamrekh RA; Babkina SS; Gilep AA; Shumyantseva VV
Biomed Khim; 2020 Jan; 66(1):64-70. PubMed ID: 32116227
[TBL] [Abstract][Full Text] [Related]
10. Predicting drug-drug interactions by electrochemically driven cytochrome P450 3A4 reactions.
Shumyantseva VV; Koroleva PI; Bulko TV; Sergeev GV; Usanov SA
Drug Metab Pers Ther; 2022 Sep; 37(3):241-248. PubMed ID: 34860476
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
12. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
13. Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells.
Schneider A; Schmalix WA; Siruguri V; de Groene EM; Horbach GJ; Kleingeist B; Lang D; Böcker R; Belloc C; Beaune P; Greim H; Doehmer J
Arch Biochem Biophys; 1996 Aug; 332(2):295-304. PubMed ID: 8806738
[TBL] [Abstract][Full Text] [Related]
14. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactions.
Hutzler JM; Melton RJ; Rumsey JM; Schnute ME; Locuson CW; Wienkers LC
Chem Res Toxicol; 2006 Dec; 19(12):1650-9. PubMed ID: 17173379
[TBL] [Abstract][Full Text] [Related]
16. Approaches for increasing the electrocatalitic efficiency of cytochrome P450 3A4.
Shumyantseva VV; Koroleva PI; Bulko TV; Shkel TV; Gilep AA; Veselovsky AV
Bioelectrochemistry; 2023 Feb; 149():108277. PubMed ID: 36198256
[TBL] [Abstract][Full Text] [Related]
17. No effect of lipoic acid on catalytic activity of cytochrome P450 3A4.
Makhova AA; Shikh EV; Bulko TV; Gilep AA; Usanov SA; Shumyantseva VV
Drug Metab Pers Ther; 2020 Jul; 35(3):. PubMed ID: 32712589
[TBL] [Abstract][Full Text] [Related]
18. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5.
Yamazaki H; Johnson WW; Ueng YF; Shimada T; Guengerich FP
J Biol Chem; 1996 Nov; 271(44):27438-44. PubMed ID: 8910324
[TBL] [Abstract][Full Text] [Related]
19. Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment.
Baas BJ; Denisov IG; Sligar SG
Arch Biochem Biophys; 2004 Oct; 430(2):218-28. PubMed ID: 15369821
[TBL] [Abstract][Full Text] [Related]
20. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes.
Yang LQ; Yu WF; Cao YF; Gong B; Chang Q; Yang GS
World J Gastroenterol; 2003 Sep; 9(9):1959-62. PubMed ID: 12970884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
